Abstract | BACKGROUND: AIM: METHODS: STUDY GROUP: eight patients (seven males) aged 22-71 years with stable Wilson disease treated from 4 to 50 years. Patients were monitored for 3 months then for 12 months on a single daily dose of trientine (15 mg/kg). RESULTS: All patients remained clinically well. ALT and AST fluctuated in some, but none required treatment stoppages or side effects. Liver synthetic function was unchanged. Mean 24-h urine copper and zinc excretions at end of treatment were 313.4 ± 191.7 and 2,214 ± 1,346 μg, respectively. CONCLUSIONS: Once-daily trientine should be explored further for possible maintenance therapy for WD. Single daily dose may improve adherence to therapy. Larger trials and longer-term follow-up will establish the safety and treatment efficacy of this once-daily treatment regimen for WD (registration: NCT01472874).
|
Authors | Aftab Ala, Ermal Aliu, Michael L Schilsky |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 60
Issue 5
Pg. 1433-9
(May 2015)
ISSN: 1573-2568 [Electronic] United States |
PMID | 25605552
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Chelating Agents
- Trientine
|
Topics |
- Administration, Oral
- Adult
- Aged
- Chelating Agents
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Hepatolenticular Degeneration
(diagnosis, drug therapy)
- Humans
- Male
- Medication Adherence
- Middle Aged
- Patient Dropouts
- Patient Satisfaction
- Pilot Projects
- Prospective Studies
- Surveys and Questionnaires
- Time Factors
- Treatment Outcome
- Trientine
(administration & dosage, adverse effects)
- Young Adult
|